Our group has also shown that the treatment of KRAS-mutant NSCLC with a PP2A molecular glue, DT-061, using both cell-based and in vivo models, induces apoptosis, inhibits tumor growth, and synergizes with the MEK1/2 inhibitor selumetinib (23, 29). The gene discussed is MAP2K1; the disease is neoplasm.